Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study

MLA

Thomas K. Waddell, et al. “Outcomes for Patients in the Pembrolizumab+axitinib Arm with Advanced Renal Cell Carcinoma (RCC) Who Completed Two Years of Treatment in the Phase III KEYNOTE-426 Study.” Journal of Clinical Oncology, vol. 39, Feb. 2021, p. 327. EBSCOhost, https://doi.org/10.1200/jco.2021.39.6_suppl.327.

APA

Thomas K. Waddell, Igor Bondarenko, Cezary Szczylik, Dmitry Nosov, Jens Bedke, Elizabeth R. Plimack, Viktor Stus, Sophie Tartas, Michael B. Atkins, Brian I. Rini, Thomas Powles, Rodolfo F. Perini, Frédéric Pouliot, Jianxin Lin, Rustem Gafanov, L Rhoda Molife, Maurice Markus, Boris Alekseev, Anna Kryzhanivska, & Raymond S. McDermott. (2021). Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study. Journal of Clinical Oncology, 39, 327. https://doi.org/10.1200/jco.2021.39.6_suppl.327

Chicago

Thomas K. Waddell, Igor Bondarenko, Cezary Szczylik, Dmitry Nosov, Jens Bedke, Elizabeth R. Plimack, Viktor Stus, et al. 2021. “Outcomes for Patients in the Pembrolizumab+axitinib Arm with Advanced Renal Cell Carcinoma (RCC) Who Completed Two Years of Treatment in the Phase III KEYNOTE-426 Study.” Journal of Clinical Oncology 39 (February): 327. doi:10.1200/jco.2021.39.6_suppl.327.